@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix go: .
@prefix Protein: .
@prefix sfam: .
@prefix geneProductOf: .
@prefix hasAgent: .
@prefix species: .
@prefix occursIn: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 hasAgent: sub:_2;
a go:0042789 .
sub:_2 geneProductOf: sfam:MEF2%20Family;
a Protein: .
sub:_3 occursIn: species:10090;
rdf:object sub:_1;
rdf:predicate belv:decreases;
rdf:subject go:0007049;
a rdf:Statement .
sub:assertion rdfs:label "bp(GOBP:\"cell cycle\") -| tscript(p(SFAM:\"MEF2 Family\"))" .
}
sub:provenance {
beldoc: dce:description "Approximately 61,000 statements.";
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
dce:title "BEL Framework Large Corpus Document";
pav:authoredBy sub:_5;
pav:version "20131211" .
sub:_4 prov:value "even though this fusion protein efficiently prevented BrdU uptake in MCK-CAT-positive cells (Figure 4h-j). As E2F1-pRb(SP) retained the anti-proliferative property of pRb but did not fully activate myogenesis on its own, we tested whether it could cooperate with MEF2C-VP16 in our myogenesis assays. The combination of MyoD+E12, MEF2C-VP16, and E2F1-pRb(SP) activated MCK-luciferase expression to a level equal to or greater than that achieved following co-transfection of MyoD+E12 with pRb (Figure 4a, compare columns 3 and 7), and led to the appearance of numerous cells in the culture that displayed very high levels of CAT staining and no BrdU incorporation (Figure 4k-m), very similar to what was observed following transfection of MyoD with pRb (Figure 4b-d). Cotransfection of E2F1-pRb(SP) and MEF2C-VP16 in the absence of MyoD did not induce the expression of MCK-CAT (data not shown). Thus, we were able to fully substitute for the loss of pRb by cotransfecting MyoD with an activated form of MEF2 and the cell-cycle-arresting molecule E2F1-pRb(SP).";
prov:wasQuotedFrom pubmed:10322110 .
sub:_5 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:10322110;
prov:wasDerivedFrom beldoc:, sub:_4 .
}
sub:pubinfo {
this: dcterms:created "2014-07-03T14:31:30.417+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}